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ABSTRACT 
 Labial adhesions are a common finding estimated to occur in 22% of prepubertal 
girls.  Symptoms are related to the accumulation of urine behind partially fused labia and 
include urinary tract infections, vulvovaginitis, pain with activity, post-void dripping of 
urine, and, in cases of complete labial fusion, urinary retention.    Although topical estrogen 
had traditionally been considered first-line therapy, this method of treatment can be 
associated with alarming side effects in prepubertal girls including breast budding and 
vaginal bleeding.  This clinical study aimed to assess the need for estrogen for treatment of 
prepubertal labial adhesions.     
 A single site, randomized, double-blinded, 21-month clinical trial was 
performed.  Prepubertal girls ages 3 months to 12 years with labial adhesions and without 
underlying dermatologic disorders, systemic conditions that can have vulvar manifestations, 
disorders requiring immunosuppressant treatment, and previous surgical separation of labial 
adhesions were included in the study.  A computer-generated block randomization design 
with blocks of 10 was used to randomize participants into the topical estrogen or topical 
emollient group.  The topical estrogen group received Estrace® Cream (Estrace vaginal 
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cream, USP, 0.01%; Warner Chilcott).  The topical emollient group received Cetaphil® 
Moisturizing Cream to resemble Estrace® cream.  The participants’ parents or guardian 
were instructed to apply the preparation to the labial adhesion with lateral traction twice 
daily.  The principal investigator, study staff and patients were blinded throughout the trial. 
The primary outcome was the comparative the effectiveness of topical emollient with 
lateral traction as compared to topical estrogen with lateral traction on the resolution of 
labial adhesions in prepubertal girls.  The secondary outcome was the change in severity of 
labial adhesion over time between the two groups.  Sample size calculations indicated 20 
girls per group would be sufficient (alpha = 0.05, power = 80%).      
Of the 43 prepubertal girls randomized, 38 (88%) completed the study.  Although 
almost twice as many patients treated with estrogen (37%) had complete resolution of the 
labial adhesion as compared to those treated with emollient (19%), this difference was not 
statistically significant (p =.206).  In addition, although there was a decrease in severity of 
labial adhesions with time for both groups, the magnitude of the improvement did not 
depend on treatment assignment.  Seventy-five percent of the variance in severity of labial 
adhesions between the 2 treatment groups was explained by time alone versus only 2 percent 
of the variance explained by the interaction between treatment and time.  The difference in 
severity of labial adhesions between the 2 treatment groups over time (interaction effect) and 
main effect of treatment were not statistically significant (p = .425 and .370 respectively).  
Topical emollient with lateral traction can be recommended for treatment of 
prepubertal labial adhesions. 
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CHAPTER 1 
 
INTRODUCTION 
 
 Labial adhesions are an acquired condition of prepubertal girls in which the labia are 
partially or completely fused over the vaginal opening, and, in severe cases, the urethra.  The 
diagnosis is made by visual inspection of the vulva.  A thin line of fusion can be seen in the 
midline of the labia fused over the vaginal opening.
1
  
 
Figure 1. Labial Adhesion 
Labial adhesions are estimated to occur in 22% of prepubertal girls and are most 
frequent in ages 3 months to 6.
2-4
  As labial adhesions typically resolve spontaneously with 
estrogen production at puberty, treatment is recommended only for prepubertal girls who are 
symptomatic.
1  
Symptoms are related to the accumulation of urine behind partially fused 
labia and include recurrent urinary tract infections and vulvovaginitis, pain with activity, 
post-void dripping of urine and, in cases of complete fusion of the labia, urinary 
retention.
1,2,5  
Some parents also request treatment for concerns about the appearance of their 
child’s external genitalia including that their child’s vagina appears “absent.”1,6  The 
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etiology of labial adhesions is unclear but is presumably related to hypoestrogenism in 
combination with vulvar irritation.
1  
Labial adhesions are not seen in newborn girls as the 
vulva are well estrogenized from maternal hormones.  The persistence of labial adhesions in 
early adolescence in the presence of endogenous pubertal estrogen levels is uncommon.
  
 In 
pubertal girls, labial adhesions are extremely rare in the absence of underlying conditions 
such as genital trauma.
7
  
 For many years, first-line treatment for labial adhesions in prepubertal girls has been 
topical estrogen.  This recommendation was based on early reports that treatment with 
topical estrogen resolved labial adhesions in 88% to 90% of cases.
4,8
  However, these were 
observational studies with small patient populations.  In one case series of 50 patients, the 
authors included in their success rate of 90% those girls who required manual separation of 
fine adhesions after treatment with topical estrogen.
4
   A prospective cohort study of only 30 
patients including five patients in a control group treated with a topical emollient reported a 
success rate of 88% for girls treated with topical estrogen.
8
  In contrast, a later retrospective 
case series in which 259 symptomatic girls with labial adhesions were treated with topical 
estrogen reported a success rate of only 47% with a 14% recurrence rate after successful 
treatment.
1
  Although regimens vary, topical estrogen is typically applied with gentle lateral 
traction to the adhesion site once or twice daily for 4 to 8 weeks.
   
However, multiple courses 
may be necessary before resolution of labial adhesions and there have been reports of use of 
topical estrogen cream for up to 36 months.
9
 This method of treatment is not without risk as 
estrogen is systemically absorbed.  Although transient, there have been reports of breast 
budding, vulvar hyperpigmentation and vaginal bleeding with the use of topical 
estrogen.
6,9,10 
 In addition there is a high risk of recurrence of labial adhesions of up to 35%  
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after treatment with topical estrogen.
11
   For labial adhesions that do not respond to medical 
therapy, manual separation with a cotton-tipped swab after application of local anesthesia 
can be attempted.
1
  Patients who do not tolerate separation in the office or who have dense 
labial adhesions require separation in a surgical setting.    
 Recently, the role of low estrogen levels as the etiology of labial adhesions and the 
use of topical estrogen for treatment of labial adhesions has been questioned.  Caglar found 
no statistically significant difference in the serum estradiol levels of prepubertal girls mean 
age 12 months with and without labial adhesions.
10  
Papagianni reported the case of a 2 year 
old girl with elevated serum estradiol levels and premature thelarche who also had a labial 
adhesion.
12  
 In a recent study comparing the use of topical estrogen therapy verses manual 
separation followed by topical estrogen for the treatment of labial adhesions in patients with 
no previous therapy,  Soyer reported a statistically significant higher success rate with the 
use of manual separation followed by topical estrogen (100%) when compared to topical 
estrogen alone (55.5% to 66.6%).
13
  In addition, the rate of recurrence was higher (11%) in 
the patients treated with estrogen alone when compared to the other treatment group in 
which there was no recurrence during a 9-month follow-up.  
 
 Although hypoestrogenism persists in children and the level of estrogen does not 
increase in girls until puberty, the peak incidence of labial adhesion in girls is at 13 to 23 
months of age.
14
  Typically, most girls no longer use diapers after the age of 3 years and are 
more mobile and active.  Caglar proposes that the decreased local irritation that accompanies 
decreased use of diapers and the increased activity which causes frequent opening of the 
labia minora prevents approximation of denuded labial epithelium and decreases the 
incidence of labial adhesions in girls older than two years.
10 
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There is no conclusive evidence that estrogen has a lytic effect on labial adhesions.
10
   
However, estrogen has been shown to accelerate cutaneous wound healing, inhibit local 
inflammatory response and enhance wound reepithelialization.
15,16
   Generally, for medical 
treatment of labial adhesions, topical estrogen is applied with gentle lateral traction to the 
adhesion site.  It is, therefore, plausible that the lateral traction results in the separation of 
labial adhesions while the use of estrogen improves healing after mechanical separation.
 
 The primary aim of this randomized clinical trial was to compare the effectiveness of 
topical emollient with lateral traction as compared to topical estrogen with lateral traction on 
the resolution of labial adhesions in prepubertal girls.  The secondary aim of this study is to 
evaluate the change in severity of labial adhesion over time between the two groups.   
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CHAPTER 2 
METHODOLOGY 
Procedures 
 This was a single site, randomized, double-blinded, 21-month clinical trial evaluating 
the comparative effectiveness of topical emollient with lateral traction versus topical 
estrogen with lateral traction for the treatment of labial adhesions in prepubertal girls.  
A block randomization design with blocks of 10 was generated by SPSS software 
(Version 22.0 SPSS Inc, Chicago, IL) and used to maintain balance of treatment 
assignments.  Treatment allocation was directed by a list of participant study ID numbers 
and corresponding random assignments prepared in advance by the study statistician and 
followed by the investigational drug services (IDS) pharmacy as each new participant 
enrolled and was assigned the subsequent study identification (ID) number.  Only the 
statistician and the pharmacy staff were aware of the assignments.  The principal 
investigator, study staff and patients were blinded throughout the trial.  Group 1 received 
Estrace® Cream (Estrace vaginal cream, USP, 0.01%; Warner Chilcott).  Group 2 received 
Cetaphil® Moisturizing Cream formulated by the IDS pharmacy at Children’s Mercy 
Hospital, Kansas City Missouri to resemble Estrace® cream.  Study medication was 
packaged in identical containers dispensed directly to the patient by the IDS pharmacy staff.   
 Potential subjects from the Pediatric and Adolescent Gynecology Clinic at 
Children’s Mercy Hospital & Clinics meeting inclusion/exclusion criteria were invited to 
participate and written consent was obtained from a parent or legal guardian.  Following 
baseline measurements, study participants were randomly assigned to either the topical 
estrogen with traction group or the topical emollient with traction group.  The participants’ 
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parents or guardian were instructed to apply the preparation to the labial adhesion with 
lateral traction twice daily.   The technique for application of the topical preparation as well 
as the technique for lateral traction was demonstrated to the participants’ parent or legal 
guardian and written instructions were provided.  After randomization, participants returned 
for assessments at 3 and 6 weeks.  Evaluations at baseline, 3 weeks and 6 weeks were 
chosen as 50% of labial adhesions resolve in 2 to 3 weeks and most labial adhesions resolve 
with 6 weeks of treatment with topical estrogen.
2  
  
 This study was submitted to the Children’s Mercy Hospital institutional review board 
and was approved after full review.  This study was also registered on ClinicalTrial.gov 
(Identifier: NCT02218463).  
Sample 
At the time of study initiation, there were no data from which to estimate the potential effect 
size between the two treatment groups, therefore a clinically meaningful failure rate was 
used for the power analysis.  Data suggest that 50% of labial adhesions treated with estrogen 
will resolve within the 3 week study period.
1
  A meaningful failure rate for the emollient 
would be a rate of only 10% resolution at 3 weeks.  Therefore, a sample size of 20 
completed participants per group was determined to have 80% power to detect a difference 
in resolution of that magnitude in labial adhesions between the two groups at the 3 week 
follow-up point.   Taking into account a 20% attrition rate, the goal was to enroll 50 patients 
to have 40 completed subjects.   
Inclusion criteria were as follows: prepubertal girls ages 3 months to 12 years with 
labial adhesions.  Exclusion criteria were as follows: presence of underlying dermatologic 
conditions such as lichen sclerosis, severe atopic dermatitis, psoriasis or vitiligo; presence of 
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systemic conditions that can have vulvar manifestations such as Crohn’s disease and Behçet 
disease; presence of disorders requiring immunosuppressant treatment; and, previous 
surgical separation of labial adhesions. 
Measures 
 The age of all enrolled patients was obtained from the chart and recorded.  At the 
initial evaluation, baseline severity and thickness of the labial adhesion was determined by 
examination by either the principal investigator or the gynecology advanced practice nurse 
practitioner using the following scales:  
 Rating of closure of the introitus at presentation was assigned a ordinal value as 
follows:  
o 0=Resolved 
o 1=25% 
o 2=50% 
o 3=75% 
o 4=100%.   
 Rating of degree of thickness of the labial adhesion was measured as:  
o 0=Resolved 
o 1=Thin 
o 2=Intermediate 
o 3= Thick. 
Additionally, the following symptoms were obtained from the participants’ parents: urinary 
tract infection (UTI), vulvovaginitis, pain, post void dribbling, and urinary retention.   After 
the initial evaluation, follow up examinations were performed at 3 weeks and again at 6 
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weeks.  The same criteria used at baseline were used to assess severity and thickness and 
whether labial adhesions were not resolved at the 3 week visit.
  
If complete resolution was 
observed at the 3 week visit, subject’s participation in the trial was concluded.  At each 
follow up examination, the presence of symptoms were recorded as were the following 
potential side effects: breast budding, vulvar hyperpigmentation, vulvar irritation, and 
vaginal bleeding. 
Statistical Analysis 
 All statistical analysis were performed using SPSS version 23.0.  Descriptive 
analyses were used to characterize the two treatment groups at baseline. For the inferential 
analysis, an intention-to-treat principle was employed. For the measurement of percent 
closure of the introitus, median values for each study group at 3 and 6 weeks respectively 
were imputed for the 4 drop outs.  Three-week data was pulled forward to the 6 week visit 
for the participant who had missing data at 6 weeks and for those that had complete 
resolution at 3 weeks.  
 To assess the primary outcome, complete resolution of labial adhesions between the 
two treatment arms, Fisher’s Exact test was used as one cell had counts of less than 5. A p-
value of less than 0.05 was considered significant. 
 To assess the effect of treatment over time on extent of resolution, a composite 
measure was created by creating a cross product of the severity and thickness ratings.  For 
the secondary analysis, the composite score was compared using a two-factor repeated 
measures ANOVA to assess the main effects of treatment group, time, and the interaction of 
time by treatment.  For this analysis, a p-value of less than 0.05 was considered significant.  
To ensure statistical conclusion validity, since the composite score was a function of ordinal 
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data, data were also analyzed using non-parametric statistics (Mann-Whitney and 
Friedman’s Chi Square) and segmenting the design. For this assessment a Bonferroni 
approach was used to control for family-wise error rate and a p-value of less than 0.01 was 
considered significant for each test.  
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CHAPTER 3 
RESULTS 
 A total of 99 children were assessed for eligibility between August 2014 and March 
2016.  Of these children,76 were eligible for the study, 43 were randomized and 38 (88%) 
completed the study (Figure 2).  Two study participants dropped out after randomization and 
2 study participants dropped out after the 3 week assessment.  Of these 4 drop outs, 2 had 
been randomized to the topical estrogen group and 2 to the topical emollient group. One 
study participant, who had been randomized to the topical emollient group, had no data 
recorded at her 6 week visit although her records indicated that she had been examined.  
 Table 1 displays the baseline characteristics of study participants in each of the 
treatment groups.  As this is a randomized controlled trial which, by definition, reduces 
selection bias and eliminates bias in treatment assignment
17
, statistical analysis of 
differences in baseline characteristics between the two groups was not performed.  The 
mean age of participants was 33 (+ 20) months in the topical emollient group and 26 (+ 21) 
months in the topical estrogen group.  Approximately half of the participants in both groups 
were characterized as having 100% closure of the introitus which, in this study, denoted the 
presence of only a pin-point opening of the adhesion which allowed passage of urine.  The 
majority of participants in both groups had a labial adhesion of intermediate thickness.  Prior 
to randomization, urinary tract infections were present in only 2 patients both of whom were 
subsequently randomized to the topical estrogen group, none of the patients had 
vulvovaginitis, only 2 patients noted pain with activity with subsequent randomization of 1 
to each treatment group, and postvoid dribbling was endorsed by only 1 patient who was 
subsequently randomized to the topical emollient group. 
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 Table 2 depicts symptoms and side effects at 3 and 6 weeks after intervention.  Only 
2 study participants reported pain with activity at baseline.  One was randomized to each 
study group.  Both reported resolution of pain at 3 weeks post intervention.  Only 1 patient 
reported postvoid dribbling at baseline.  She was randomized to the topical emollient group 
and had persistent postvoid dribbling at 6 weeks post intervention. Her labial adhesion did 
not resolve by the end of the study.  There were no report side effects of breast budding, 
vulvar hyperpigmentation and vaginal bleeding thorough the study period.  Two patients, 
one randomized to each study group, reported vulvar irritation at only at 6 weeks post 
intervention.  There were no serious adverse events during the study.   
 The difference in complete resolution between participants randomized to the topical 
emollient group as compared to those randomized to the topical estrogen group is depicted 
in Table 3.  For this analysis, intention-to-treat was used wherein dropouts were assigned as 
not completely resolved.  Although almost twice as many patients treated with estrogen 
(37%) had complete resolution of the labial adhesion as compared to those treated with 
emollient (19%), this difference was not statistically significant (p =.206).  
 Response to treatment of labial adhesion is dependent not only upon the size of the 
adhesion but also the thickness.   A more accurate measurement of response to treatment 
would, therefore, incorporate both measurements.  For this study, the percentage of closure 
of the introitus at presentation was assigned an ordinal value as follows: 1=25%, 2=50%, 
3=75%, and 4=100%.  The degree of thickness of the labial adhesion was also measured in a 
similar fashion: 1=thin, 2=intermediate and 3= thick. Those that were resolved received a 
rating of 0 on both scales.  A composite severity scale was created by multiplying the value 
assigned to the percentage of introital closure by that assigned to the thickness of the 
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adhesion for each of the 3 study visits.  This allowed a comparison of treatment effect 
between each group over time wherein a lower composite severity score corresponded to a 
less severe labial adhesion (Table 4).  Although there was a decrease in severity of labial 
adhesions with time for both groups, the magnitude of the improvement did not depend on 
treatment assignment (Figure3).  Seventy-five percent of the variance in severity of labial 
adhesions between the 2 treatment groups was explained by time alone versus only 2 percent 
of the variance explained by the interaction between treatment and time.  In addition, the 
difference in severity of labial adhesions between the 2 treatment groups over time 
(interaction effect) and main effect of treatment were not statistically significant (p = .425 
and .370 respectively).     
 To confirm that the use of parametric analysis was a valid statistical decision for the 
assessment of degree of severity of labial adhesions over time, a non-parametric analysis 
was also performed (Table 5).   As 5 analyses were performed, a Bonferroni correction was 
applied and each analysis testes at significant p value of .01.  Again, the difference in 
severity of labial adhesion at baseline, 3 weeks and 6 weeks was not statistically significant 
between groups. However, the difference in the composite severity score over time within 
each treatment group was statistically significant (p<.0001).  These findings validate the use 
of parametric analysis to assess the resolution of labial adhesions over time. 
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CONSORT 2010 Flow Diagram 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CONSORT Flow Diagram 
 
 
Assessed for eligibility (n=99) 
Excluded (n= 56 ) 
   Not meeting inclusion criteria (n= 23 ) 
   Declined to participate (n= 33 ) 
 
Analysed  (n=21) 
 Excluded from analysis (n=0 ) 
Lost to follow-up (n= 2 ) 
No data documented (n= 1 ) 
Allocated to topical emollient group (n=21) 
 Received allocated intervention (n=21) 
 Did not receive allocated intervention (n=0 ) 
Lost to follow-up (n= 2 ) 
 
Allocated to topical estrogen group (n=22) 
 Received allocated intervention (n=22) 
 Did not receive allocated intervention (n=0  ) 
Analysed (n=22) 
 Excluded from analysis (n=0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=43) 
Enrollment 
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Table 1 Baseline Characteristics of Study Participants 
 
Characteristics 
Topical 
Emollient 
N = 21, n (%) 
Topical 
Estrogen 
N = 22, n (%) 
Mean age in months + SD 33 + 20 26 + 21 
n (%) introital closure   
     25% 1 (5) 0 (0) 
     50% 5 (24) 4 (18) 
     75% 4 (19) 7 (32) 
     100% 11 (52) 11 (50) 
Thickness of labial adhesion     
     Thin 5 (24) 4 (18) 
     Intermediate 14 (67) 17 (77) 
     Thick  2 (10) 1 (5) 
UTI 0 (0) 2 (9) 
Vulvovaginitis  0 (0) 0 (0) 
Pain with activity 1 (5) 1 (5) 
Postvoid dribbling 1 (5) 0 (0) 
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Table 2 Symptoms and Side Effects After Intervention 
 
Variable 
Topical 
Emollient 
N = 21, n (%) 
Topical  
Estrogen 
N = 22, n (%) 
At 3 weeks   
     UTI 0 (0) 0 (0) 
     Vulvovaginitis 0 (0) 0 (0) 
     Pain with activity 0 (0) 0 (0) 
     Postvoid dribbling 1 (5) 0 (0) 
     Urinary retention 0 (0) 0 (0) 
At 6 weeks   
     UTI 0 (0)  0 (0) 
     Vulvovaginitis 0 (0) 0 (0) 
     Pain with activity 0 (0) 0 (0) 
     Postvoid dribbling 1 (5) 0 (0) 
     Urinary retention 0 (0) 0 (0) 
At 3 weeks   
     Breast budding  0 (0) 0(0) 
     Vulvar hyperpigmentation 0 (0) 0 (0) 
     Vulvar irritation 0(0) 0(0) 
     Vaginal Bleeding  0(0) 0 (0) 
At 6 weeks   
 16 
 
     Breast budding 0 (0) 0 (0) 
     Vulvar hyperpigmentation 0 (0) 0 (0) 
     Vulvar irritation 1 (5) 1(5)  
     Vaginal Bleeding 0 (0) 0 (0) 
 
 
Table 3 Complete Resolution 
 
Complete Resolution 
Topical 
Emollient 
N = 21, n 
(%) 
Topical  
Estrogen 
N = 22, n (%) 
P value 
Yes 4 (19) 8 (36) .206 
No 17 (81) 14 (64)  
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Table 4 Composite Severity Scale of Labial Adhesion Over Time (Parametric Analysis) 
 
Variable 
Topical 
Emollient 
N = 21 
Topical  
Estrogen 
N = 22 
P value ^ 
Composite Severity Scale   Treatment: .370 
Time: .0001 
Interaction: .425 
Baseline 6.3 (3.1) 6.2 (2.0)  
3weeks 2.3 (2.4) 1.5 (1.7)  
6weeks 1.9 (2.1) 1.6 (1.9)  
Data presented as mean + SD 
^ Repeat measure ANOVA: main effects are for treatment (emollient versus estrogen), time 
(baseline, 3 weeks and 6 weeks after intervention) and treatment by time interaction. 
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Figure 3. Composite Severity Scale of Labial Adhesion Over Time 
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Table 5 Means (SD) of Composite Severity Scale of Labial Adhesion Over Time (Non-
Parametric Analysis) 
 
Composite Severity Scale Baseline 3 weeks 6 weeks P value ^ 
Topical Emollient 
N = 21 
6.3 (3.1) 2.3 (2.4) 1.9 (2.1) .0001 
Topical  
Estrogen 
N = 22 
6.2 (2.0) 1.5 (1.7) 1.3 (1.6) .0001 
P value 
^^ 
.898 .250 .281  
^ Friedman Chi-Square, ^^Mann-Whitney 
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CHAPTER 4 
DISCUSSION 
Although the exact etiology of prepubertal labial adhesions is unknown, vulvar 
inflammation in a hypoestrogenic milieu is the prevailing hypothesis.
1,18
  The traditional 
treatment for labial adhesions has been the application of topical estrogen with or without 
manual separation.
19
  There is, however, no evidence that estrogen has a lytic effect on labial 
adhesions.  In addition, topical estrogen can cause alarming side effects such as breast 
budding and vaginal bleeding in prepubertal girls.  The question remains as to whether 
lateral traction with the use of a topical emollient would have comparable results as lateral 
traction with the use of estrogen.  This clinical trial was primarily undertaken to assess the 
need for estrogen for treatment of prepubertal labial adhesions. In this study, only 36% of 
patients treated with twice daily application of topical estrogen with lateral traction during 6 
weeks had complete resolution of labial adhesions. This is considerably lower than 
previously reported resolution rates as high as 100% with use of topical estrogen.  Carpraro 
and Greenberg described a retrospective case series including 66% of patients with 
adhesions “involving the entire length of the labia minora.”4 Forty-two of 47 patients (89%) 
had good results with a 2 to 4 week course of once daily topical estrogen.  However, 
included in the success rate were patients with “fine adhesions” who were treated with 
manual separation.  Aribarg reported a prospective cohort study in which 22 of 25 patients 
(88%) were successfully treated with once daily topical estrogen for 1 to 4 weeks.
8
  All 
patients had adhesions “involving the entire length of the labia minora.”  This study, 
however, lacked blinding of treatment method and the control group consisted of only 5 
patients treated with a topical emollient for 1 month.  Leung et al described a prospective 
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case series of 20 patients with labial adhesions in which all patients (100%) responded to 
treatment with topical estrogen applied twice daily.
20
  Although the authors described the 
severity of the adhesions as covering at least 50% of the vaginal opening, it is possible that 
lower success rate in the current study is attributable to a higher percentage of more severe 
labial adhesions amongst the study population wherein 51% (22 of 43) of participants had 
100% closure of the introitus with only a pin-point opening.  In addition, patients in Leung’s 
series were treated with topical estrogen for up to 14 weeks as compared to up to only 6 
weeks of treatment in the current trial.  
With regards to the complete resolution of labial adhesions in this study, the 
difference between the two groups was clinically significant (37% treated with estrogen 
versus 19% treated with emollient) albeit not statistically significant. It would not be 
surprising for a parent made aware that estrogen is almost twice as likely as emollient to 
result in complete resolution of labial adhesions to choose the former for their child.  This is 
especially so given the equally low (5%) side effect rate of vulvar irritation between the two 
groups, the only side effect of treatment noted in this study.  The lack of statistical 
significance in complete resolution in this study may be attributable to the use of previously 
reported treatment success rates to estimate a meaningful difference between the two 
treatment groups.  The relatively small sample size of this study likely contributed to the 
inability to obtain statistically significant results for a relatively small difference in treatment 
outcomes between the two treatment groups.   
Interestingly, in a retrospective case series of 259 patients wherein patients were 
treated with topical estrogen for 10 to 14 days, Muram reported a success rate of only 47% 
despite the fact that 76% of these girls were reported to have thin, translucent labial 
 22 
 
adhesions.
1
  In the current study, there was a 36% complete resolution rate despite a much 
smaller percentage of patients (21%) with thin adhesions.  The relative difference in results 
between these two studies reflects the importance of using both thickness and size of labial 
adhesions as a measure of severity in assessing treatment response.  When comparing the 
relative effect of treatment with estrogen as compared to emollient in this study, use of the 
composite severity score showed that time alone rather than method of treatment explained 
the majority of the variance in severity of labial adhesions between the two groups.  
However, many parents may have found it difficult to be completely complaint with the 
recommendation to apply topical estrogen twice daily.  Thus, the lack of a statistically 
significant difference in the severity of labial adhesions when evaluating treatment effect 
alone may reflect lack of adherence to the recommended frequency of treatment. 
In a recent review of clinical recommendations for the treatment of labial adhesions 
topical estrogen was still described as “the best initial therapeutic recommendation.”18  
However, the results of this study suggest that topical estrogen is not essential in the 
treatment of labial adhesions.  The use of a topical emollient with lateral traction does result 
in a decrease in severity of labial adhesions over 3 and 6 weeks of treatment.  This finding 
has clinical significance in that families who are unwilling to use topical estrogen due to fear 
of potential side effects of hormonal therapy or are unable to purchase topical estrogen due 
to cost have the option of treating labial adhesions using a relatively inexpensive topical 
emollient with lateral traction.   
This study does have limitations.  The adherence to treatment was obtained through 
parent report rather than weighing the returned medication initially provided by the IDS 
pharmacy at the end of the study period.  As parents may not have been willing to admit a 
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lack of compliance with recommended therapy, the lower resolution rates of labial adhesions 
described in this study may be a function of lack of adherence to the treatment protocol.  In 
addition, although all study participants were evaluated by one of two investigators, as 
neither intra- nor inter-observer variability in the assessment of labial adhesions were 
assessed, the measurements must be considered subjective.   
Future studies with larger sample size should include more objective means of 
assessing the severity of labial adhesions as with photo documentation and assessments of 
both intra- and inter-observer variability.   
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